Perspective Therapeutics, Inc.
CATX · XNYSCIK 728387fmd_0ASACQEWEY5T1JJAJZJ4825A99Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 65 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 6 | 7 | 10 | 10 | – | 0 | 1 | – | – |
| Cost of revenue | 4 | 4 | 4 | 5 | 5 | 6 | – | – | – | – |
| Gross profit | 1 | 2 | 3 | 5 | 5 | – | 0 | 1 | – | – |
| Research and development | 1 | 2 | 1 | 1 | 1 | – | 1 | 21 | 42 | 84 |
| Selling, general and administrative | 6 | 7 | 7 | 8 | 7 | 9 | – | – | – | – |
| Total operating expenses | 7 | 9 | 8 | 9 | 9 | – | 9 | 42 | 92 | 114 |
| Operating income | (6) | (7) | (5) | (3) | (3) | – | (9) | (41) | (91) | (114) |
| Interest expense | 0 | – | – | – | – | – | 0 | 0 | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | 1 | 1 | 11 | 8 |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | – | 1 | 1 | 10 | 9 |
| Income before taxes | – | – | – | – | – | – | (8) | (40) | (80) | (104) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | – | 0 | (3) | (2) | (1) |
| Net income from continuing operations | – | – | – | – | – | – | (8) | (37) | (78) | (104) |
| Net income | (6) | (7) | (5) | (3) | (3) | – | (11) | (47) | (79) | (103) |
| Net income to common shareholders | (6) | (7) | (5) | (3) | (3) | (7) | – | – | – | – |